Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Co. Ltd.

www.eisai.com

Latest From Eisai Co. Ltd.

Biopharma COVID-19 Collaborations May Avoid Antitrust Hurdles, FTC And DOJ Suggest

FTC and DoJ issue guidance for businesses working together to tackle coronavirus pandemic; BIO is 'pleased' they intend to help facilitate critical partnerships.

Coronavirus COVID-19 Enforcement

Coronavirus Update: R&D Starts, Product Delays, Continuing Collaboration

In addition to our daily in-depth coverage of key events relating to the coronavirus pandemic, we’re bringing you a periodic round-up of other significant developments. 

Coronavirus COVID-19 Drug Review

Finance Watch: Kymera Will Start Protein Degrader Clinical Trials With $102m VC Round

Private Company Edition: Kymera said it will take up to three programs into the clinic by next year. Also, three new life science funds recently launched, including a Gates Foundation-backed accelerator for COVID-19 treatments, and Cell Medica reemerges as Kuur with new funding for CAR-NKT therapies.

Financing Coronavirus COVID-19

Deal Watch: Vir Partnering With Alnylam, WuXi On Coronavirus Treatments

US biotech expands 2017 collaboration with Alnylam and inks collaboration with WuXi. Plus deals involving AbbVie, Allergan, Amazon, Thermo Fisher, Qiagen, Boehringer Ingelheim, Trutino, Taiho, Arcus, Eisai, Fuji Yakuhin, Hikma, Glenmark, Hanmi, GC, Bayer, GW.

Deals M & A
See All

Company Information

UsernamePublicRestriction

Register